Factors predicting the instant effect of motor function after subthalamic nucleus deep brain stimulation in Parkinson’s disease
© The Author(s). 2017
Received: 15 February 2017
Accepted: 3 May 2017
Published: 26 May 2017
Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for Parkinson’s disease (PD), the predictive effect of levodopa responsiveness on surgical outcomes was confirmed by some studies, however there were different conclusions about that through long- and short-term follow-ups. We aimed to investigate the factors which influence the predictive value of levodopa responsiveness, and discover more predictive factors of surgical outcomes.
Twenty-three PD patients underwent bilateral STN-DBS and completed our follow-up. Clinical evaluations were performed 1 week before and 3 months after surgery.
STN-DBS significantly improved motor function of PD patients after 3 months; preoperative levodopa responsiveness and disease subtype predicted the effect of DBS on motor function; gender, disease duration and duration of motor fluctuations modified the predictive effect of levodopa responsiveness on motor improvement; the duration of motor fluctuations and severity of preoperative motor symptoms modified the predictive effect of disease subtype on motor improvement.
The intensity of levodopa responsiveness served as a predictor of motor improvement more accurately in female patients, patients with shorter disease duration or shorter motor fluctuations; PD patients with dominant axial symptoms benefit less from STN-DBS compared to those with limb-predominant symptoms, especially in their later disease stage.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by progressive loss of dopaminergic neurons in the substantia nigra; the cardinal clinical motor symptoms include tremor, rigidity, bradykinesia and axial symptoms . Levodopa replacement therapy is the standard treatment for PD but causes motor complications as the disease progresses . Subsequently, bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) is used for patients with drug-refractory tremor or patients with intolerable motor complications. The benefits of STN-DBS are incontestable and have been proven by short-term and long-term follow-up studies [2–7].
Factors related to the outcomes of STN-DBS are a major concern to clinicians who want to predict the surgical effects in patients before the operation. P.D. Charles et al. and Jianyu Li respectively reported that patients with better preoperative levodopa responsiveness and younger age showed greater effects of surgery after 3 months  and after a long-term follow-up ; Hae Yu Kim et al.  noted that preoperative levodopa responsiveness, gender, age and magnitude of the Hoehn and Yahr stage (H&Y stage) before surgery were predictive of surgical outcomes with more than 3 years of follow-up. However, Tsai et al.  discussed that preoperative levodopa responsiveness only led to consistent improvement in part III of the Unified Parkinson Disease Rating Scale (UPDRS III) 3 months after STN-DBS and this predictive effect did not exist after 18 months. They also reported that disease duration, severity or H&Y stage did not predict improvement from short- and long-term STN-DBS; this result was contrary to the findings of other studies [4, 8]. While questions remain regarding why there are differing correlations between levodopa responsiveness and surgical improvement in long-term follow-ups or compared to that of short-term follow-up, and whether there are unknown factors influencing the predictive effects of levodopa responsiveness on DBS outcomes. Additionally, no consensus exists regarding the above-mentioned predictors, and whether there are any other characteristics that can predict the effects of surgery yet to be confirmed.
In the present retrospective study, we confirmed the effects of bilateral STN-DBS with a 3-month follow-up. The 3 month was selected as a short-term follow-up because optimal surgical effects generally appear 3–6 months postoperatively  and most patients attained a relatively stable condition 3 months postoperatively . Moreover, we aimed to identify other predictive factors for the effects of STN-DBS after 3 months, and it was worth emphasizing that we further performed stratified analyses to explore which factors modify the predictive effects of preoperative levodopa responsiveness and other analyzed predictors of postoperative motor improvement.
We studied 27 consecutive PD patients who underwent bilateral STN-DBS in the First Affiliated Hospital of China Medical University from November 2014 to November 2015, including 22 Medtronic DBS system and 5 PINS DBS system. All patients enrolled in the study have written informed consent, and the local ethics committee approved the study. The inclusion criteria for the study were as follows: 1) patients must were diagnosed as idiopathic Parkinson’s disease by movement disorder neurologists based on the UK PD Brain Bank Criteria ; 2) disease duration > = 4 years; 3) were effective to levodopa; 4) with motor fluctuations or wearing-off phenomenon; 5) can cooperate with our follow-up. Exclusion criteria including: 1) obvious complications after surgery, such as hemorrhage, serious infection; 2) with dementia or severe psychotic symptoms; 3) marked cerebral atrophy or other abnormities on MRI.
We located the subthalamic nucleus by preoperative magnetic resonance imaging (MRI 3.0 T) with Leksell stereotactic frame, then compute accurate coordinates of the target by surgical-plan system, the subthalamic nuclei dorsolateral part was selected as the target; intraoperative microelectrode localization was taken use of the electrophysiological recordings, then we made a stimulation test to observe the reaction of patients to different voltages after electrode implantation, an impulse generator (IPG) was implanted subcutaneously when patients were under general anesthesia. All patients underwent MRI (1.5 T) postoperatively for the assessment of target location and surgical complications (Fig. 1). Patients followed the doctor’s advices to continue to take medicine and without stimulation settings temporarily.
Approximately 1 month after surgery, we turned on the IPG when patients were totally at off-medication state (drug withdrawal more than 6 h), through repetitive tests, all the contacts were tested according to a standard protocol . We set frequency at 130 Hz and pulse width at 60 us generally, the amplitude was progressively increased from 0 to 5–6 V with increments of 0.5–1.0 V or until side effects appeared. The optimal electrode contacts and voltage with the lowest threshold for inducing a beneficial results and the highest threshold for leading side effects were finally selected for chronic stimulation . After setting up suitable parameters, we adjusted the dopaminergic medication based on the patient’s response to stimulation or just followed the preoperative medication plan. Then patients continued to observe at home, and accompanied with our telephone follow-up, patients came back to program when they feel uncomfortable, we adjusted the parameters on the basis of their symptoms, until up to a steady state.
Acute levodopa challenge test: UPDRS III was evaluated when patients took no medicine for at least 12 h (usually overnight) which defined as “off-medication” or baseline state , and in the course of the maximal clinical benefit after administration of a dose of Madopar which was about 50 mg higher than the usual morning dose (“on-medication”) , the levodopa responsiveness which refers to the percentage improvement of levodopa challenge test was equivalent to (UPDRS III score of the baseline state - UPDRS III score of best state)/UPDRS III score of baseline*100%.
The akinesia scores include items 23–26 of UPDRS part III; the scores of axial symptoms include dysphonia, neck rigidity, arising from a chair, gait, and postural instability (items 18, 22 along with 27–30 of UPDRS III) .
The severity of Parkinsonism was evaluated by the scores of UPDRS III and H&Y stage in off-medication condition respectively.
LEDD refers to levodopa equivalent daily dose which was calculated as the dose of dopamine agonist plus levodopa and MAO-B inhibitor, according to the following formula: 100 mg Madopar = 1 mg pramipexole = 100 mg piribedil = 10 mg selegiline; each dose of levodopa was 25% more effective with entacapone. [7, 17].
Duration of motor fluctuations refers to the time from wearing-off symptoms emerge to the time of preoperative evaluation.
Based on the predominant motor features in daily living activities and motor scores of UPDRS, the disease subtype of an individual patient was classified as posture instability and gait difficulty (PIGD)  and limb-predominant symptoms (LPS). PIGD was defined as the scores of items 28–30, LPS was defined as the total scores of limb tremor, limb rigidity and akinesia (items 23–26). We used the ratio of the scores of LPS to the scores of PIGD to judge which subtype the patients belong to (>6 belong to LPS, <6 belong to PIGD, when the rate equal to or very close to 6, we grouped the patients according to their main complaints).
Three months after STN-DBS, patients came to program the parameters, they must withdraw drugs for at least 6 h, when doctors finished the programming and patients reached to an ideal state, we assessed the score of UPDRS III at off-medication/on-stimulation condition.
The motor effects of STN-DBS was evaluated by the difference of UPDRSIII scores at off-medication state before and after operation, improvement rate was defined as follows: (preoperative UPDRS III score - postoperative UPDRS III score)/preoperative score *100%.
The effects of bilateral STN-DBS on parkinsonian motor symptoms were evaluated using Wilcoxon signed rank test (Table 2). Then we performed univariate analysis and chose the variables whose p value was less than 0.1 or with assured clinical significance, next we did multivariate analysis after adjusting the potential confounders to estimate the independent relationship between postoperative motor function improvement and each related factors. When performed further stratified analysis, we determined the cut-off point of disease duration (<10 years, > = 10 years) based on that PD patients progressed to severe disability after about 10 years of the onset , the dividing line of duration of motor fluctuations (<=3 years, >3 years) was determined by reference to previous studies [16, 20, 21], and we chose the mean preoperative scores of UPDRS III as cut-off point (<=50, >50) since no clear cut-off has been confirmed. A p value less than 0.05 was regarded as statistically significant. All analyses were performed using Empower (R) (www.empowerstats.com, X&Y solutions, inc. Boston MA) and R (http://www.R-project.org).
Demography and baseline characteristics of the PD patients
Demography and baseline characteristics of study subjects
Age of onset, y
50.4 ± 8.5
11.3 ± 5.8
Age of surgery, y
61.7 ± 8.3
H&Y stage (off-med)
Levodopa responsiveness, %
62.5 ± 19.3
999.3 ± 516.7
Motor fluctuations duration, y
5.4 ± 3.9
Baseline UPDRSIII scores (off-med)
50.2 ± 18.2
STN-DBS significantly improved the postoperative motor function of PD patients
Comparison between baseline and 3 months postoperatively
Range of possible scores
Preoperative baseline (N = 23)
3 months after surgery off-medication/on-stimulation (N = 23)
50.15 ± 18.19
21.94 ± 11.69; 56%
8.67 ± 7.85
1.44 ± 2.65; 83%
10.76 ± 4.82
3.71 ± 3.33; 66%
19.5 ± 8.95
8.98 ± 6.48; 54%
11.17 ± 5.35
6.76 ± 3.84; 40%
999.32 ± 516.69
797.52 ± 414.45; 20%
Preoperative levodopa responsiveness and disease subtype influenced the effect of DBS operation on motor function
The correlations between various factors and postoperative improvement of motor function
Age of onset, y
Age of surgery, y
H&Y stage (Mild/Severe)
Levodopa responsiveness, %
Motor fluctuations duration, y
Disease subtype (PIGD/LPS)
Baseline UPDRSIII scores
Gender, disease duration and duration of motor fluctuations modified the effect of preoperative levodopa responsiveness on postoperative motor improvement
Factors that modify the predictive effects of levodopa responsiveness and disease subtype on motor improvement
Preoperative levodopa responsiveness
Disease duration, y
> = 10
Motor fluctuations duration, y
Motor fluctuations duration, y
Each 1% increment of preoperative levodopa responsiveness led to a 1.1% increase of motor improvement in female group (β = 1.1, 95% CI 0.3,1.9, p = 0.0294), while there was no statistical significance in male patients (Table 4); as each increase of 1% of preoperative levodopa responsiveness, the motor function improved 2.0% in patients with disease duration less than 10 years (β = 2.0, 95% CI 1.1,2.9, p = 0.0021), and no statistical significance in patients with longer disease duration (>10 years); each 1% increment of preoperative levodopa responsiveness led to a 3.1% increase of postoperative motor improvement in patients whose motor fluctuations appeared less than 3 years (β = 3.1, 95% CI 0.8,5.5, p = 0.0393), and no statistical significance in the others with motor fluctuations longer than 3 years (Table 4). Moreover, when stratified by factors such as age of onset, age of surgery and H&Y stage, we not found more other factors which can influenced the predicting power of Levodopa responsiveness.
The duration of motor fluctuations and severity of preoperative motor symptoms modified the effect of disease subtype on postoperative motor improvement
The results of stratified analysis in Table 4 showed that more obvious difference was existed in patients with longer motor fluctuations (> = 3 years), in other words, in those late-stage operated patients with motor fluctuation longer than 3 years, the PIGD group was 38.4% less improved than LPS group (β = −38.4, 95% CI -67.1, −9.7, p = 0.039); additionally, in patients with more severe motor symptoms preoperatively whose baseline UPDRSIII score > 50, the PIGD group was 41.1% less improved than LPS group (β = −41.1, 95% CI -61.8, −20.4, p = 0.03); we found there was no difference of surgery effect between PIGD and LPS group when stratified by other factors.
Bilateral STN-DBS is widely used to treat PD and its distinct effects have been confirmed [2, 3, 6, 7, 11]. Compared with the “off-medication” condition prior to surgery, bilateral STN-DBS greatly improved the motor function of PD patients in “off-medication/on-stimulation” condition 3 months after surgery in our study. The total score of UPDRS III was significantly reduced by 56% of baseline. Scores of motor symptoms including tremor, rigidity, akinesia, and axial symptoms all decreased postoperatively, of these, tremor demonstrated the most improvement (83%) and axial symptoms showed minimal change (40%). In addition, postoperative medication dosage showed a marked decrease compared to preoperative dosage requirements.
The marked effects of STN-DBS after both short-term and long-term follow-up are well known, however, for clinicians, it is more important to evaluate the variables that may influence the clinical outcomes of surgery to optimize the timing of an operation and to predict the therapeutic effects of surgery as accurately as possible. Preoperative levodopa responsiveness is a well-established predictor of motor improvements after STN-DBS therapy [4, 6, 10, 22]. In our study, multivariate analyses demonstrated a positive and nearly statistically significant correlation between levodopa responsiveness and postoperative motor improvement (p = 0.055), where the p value may be attributed to the small sample size of our study. After adjusting for potential confounds in the analyses, stratifying for gender, disease duration and duration of motor fluctuations, a significant association was found between levodopa responsiveness and postoperative motor improvement.
The strong predicting effect of levodopa responsiveness generally suggests that the resolution of PD symptoms with DBS is more related to the degeneration of the dopaminergic system; greater involvement of other neurotransmitter systems, such as acetylcholine and noradrenaline, in the disease may contribute to the less predicting effect of levodopa responsiveness. Thus, our study demonstrates the three variables that may exert influence on the predictive power of levodopa responsiveness on postoperative motor improvements. The three significant variables are female gender, shorter disease duration, and shorter duration of motor fluctuations. This result not meant a great DBS response in these people or a poor surgical response in the male patients or patients with motor fluctuation more than 3 years or disease duration longer than 10 years, our point here is to tell which subset of patients can be more accurately predicted by preoperative levodopa responsiveness rather than tell the clues for worse DBS result.
In female patients, each 1% increment of preoperative levodopa responsiveness led to a 1.1% increase of postoperative motor improvement (p < 0.05), these data suggest that preoperative levodopa responsiveness may be a more accurate predictor for the outcomes of motor function after STN-DBS in female PD patients. We supposed this result may be related to the greater survival of dopaminergic neurons in women owing to the protective role of estrogens against the degeneration of dopaminergic neurons which had been suggested by primate model tests [23–25] and a clinical and epidemiological study ; in addition, estrogens were affirmed to prevent the dopamine depletion in studies using rodent PD models induced by 6-hydroxydopamine  and by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) . Accordingly, more dopaminergic neurons survived in female PD patient suggesting less disease severity, and DBS mainly ameliorated dopaminergic-related symptoms , thus, better responses to levodopa preoperatively predict greater improvement in motor function after STN-DBS in female PD patients.
The other two variables that influenced the predictive potency of levodopa responsiveness on postoperative motor improvement were shorter disease duration (< 10 years) and shorter duration of motor fluctuations (< 3 years) which both imply a DBS operation in the early stages of the disease, a so-called “early stimulated” condition. Similarly, early-stimulated groups also have fewer non-dopaminergic symptoms, including freezing of gait, postural instability, falls, or cognitive disorders; thus, parkinsonian symptoms in the early stages improve with levodopa supplementation or DBS as well. The biochemical mechanism in the late stages of PD, as suggested by a longer disease duration or longer time of motor fluctuation, was not only related to the loss of nigrostriatal dopaminergic neurons but also the participation of other non-dopaminergic systems, such as loss of noradrenaline in the locus coeruleus (LC), glutamatergic hyperactivity and loss of cholinergic pedunculopontine nucleus (PPN) neurons, as described by David Devos et al. . In sum, we supposed that preoperative levodopa responsiveness serves as a predictor for DBS outcomes more precisely in early-stage PD patients than late-stage patients. Generally, the PD symptoms expected to be resolved with DBS are those responsive to levodopa supplementation, which suggests that DBS mainly exerts a dopaminergic-based effect. The two variables in our study that exerted greater influence on the relationship between levodopa responsiveness and postoperative motor improvement are related to better preservation of dopamine neurons or less severity of the disease.
Another variable predicting postoperative motor improvement in our study was the subtype of disease before surgery. We observed a significant difference in motor improvement between two predominant subtypes; the PIGD group showed poorer amelioration than the LPS group (p < 0.05), in other words, patients with dominant symptoms of LPS preoperatively gained greater motor function improvements than those in the PIGD group. After further stratified analyses, we found this difference between the two subtypes was notable in patients with longer duration of motor fluctuations (p < 0.05) and in patients with severe motor symptoms before surgery (p < 0.05); these findings suggest that PIGD patients at a late stage of PD would benefit less from the operation than LPS patients and an early recommendation for the operation for such subtype would be desirable. Given that motor function improvement with DBS manifests primarily in dopaminergic-related symptoms, it is conceivable to understand this result since for PIGD patients, the major symptoms such as falling, balancing dysfunction and gait disorders are axial symptoms, which are not completely alleviated by levodopa but also much related to non-dopamineric neurotransmitters [29, 31] and are involved in later stages of the disease [30–32].
One major shortcoming of our study was the small sample size of 23 patients, which decreased the p value of our statistical results. Other factors related to the surgical outcomes and the predictors reported in other studies may be confirmed through the statistical analysis of a larger patient population. Another limitation of this study was that we collected UPDRS III data but not UPDRS II and IV data, so other patient aspects were not evaluated. We expect that future studies with larger patient populations will confirm these findings.
The intensity of preoperative levodopa responsiveness served as a predictor of motor improvement more accurately in female patients, and patients with short disease duration or shorter motor fluctuations. Patients with dominant axial symptoms as PIGD ones benefit less from STN-DBS compared to those with limb-predominant symptoms, especially in their later disease stage or with more severe motor symptoms before surgery. So it is natural and reasonable to recommend the operation to levodopa-responsive patients especially the female, patients in early stage of disease and PIGD patients at their early stage.
We are grateful for support from Professor Chang-Zhong Chen and Dr. Xing-Lin Chen who come from the United States X&Y Solutions software company, we thank they for guidance on statistical analysis by EmpowerStats.
This study was funded by the National Nature Science Foundation of China (grant.no.81371421).
Availability of data and materials
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
XLS: study design, data collection, statistical analysis and draft the manuscript. XGL: participated in study design, analysis of results and revision of manuscript. HL: manuscript revision. JW: design and implementation of surgical procedures. YR: critical revision of the manuscript for important intellectual content. ZYH: study supervision. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
Ethics approval and consent to participate
All patients enrolled in the study have written informed consent, and the local ethics committee approved the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lang AE, Lozano AM. Parkinson’s disease. First of two parts. New Engl J Med. 1998;339:1044–53.View ArticlePubMedGoogle Scholar
- Tao Y, Liang G. Effect of subthalamic nuclei electrical stimulation in the treatment of Parkinson's disease. Cell Biochem Biophys. 2015;71(1):113–7.View ArticlePubMedGoogle Scholar
- Chiou SM, Lin YC, Huang HM. One-year outcome of bilateral Subthalamic stimulation in Parkinson disease: an eastern experience. World Neurosurg. 2015;84(5):1294–8.View ArticlePubMedGoogle Scholar
- Kim HY, Chang WS, Kang DW, Sohn YH, Lee MS, Chang JW. Factors related to outcomes of subthalamic deep brain stimulation in Parkinson's disease. J Korean Neurosurg Soc. 2013;54(2):118–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Tir M, Devos D, Blond S, Touzet G, Reyns N, Duhamel A, Cottencin O, Dujardin K, Cassim F, Destée A, Defebvre L, Krystkowiak P. Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients. Neurosurgery. 2007;61(2):297–304.View ArticlePubMedGoogle Scholar
- Li J, Zhang Y, Li Y. Long-term follow-up of bilateral subthalamic nucleus stimulation in Chinese Parkinson's disease patients. Br J Neurosurg. 2015;29(3):329–33.View ArticlePubMedGoogle Scholar
- Jiang LL, Liu JL, Fu XL, Xian WB, Gu J, Liu YM, Ye J, Chen J, Qian H, Xu SH, et al. Long-term efficacy of Subthalamic nucleus deep brain stimulation in Parkinson's disease: a 5-year follow-up study in China. Chin Med J. 2015;128(18):2433–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Charles PD, Blercom NV, Krack P, Lee SL, Xie J, Besson G, Benabid A-L, Pollak P. Predictors of effective bilateral subthalamic nucleusstimulation for PD. Neurology. 2002;59:932–4.View ArticlePubMedGoogle Scholar
- Tsai ST, Lin SH, Chou YC, Pan YH, Hung HY, Li CW, Lin SZ, Chen SY. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects. Stereotact Funct Neurosurg. 2009;87(4):241–8.View ArticlePubMedGoogle Scholar
- Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165.View ArticlePubMedGoogle Scholar
- Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the Subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 1998;339:1105–11.View ArticlePubMedGoogle Scholar
- Hughes AJDS, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord. 2006;21(Suppl 14):S284–9.View ArticlePubMedGoogle Scholar
- Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7(1):2–13.View ArticlePubMedGoogle Scholar
- Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, FRCP CC, Eichhorn T, Melamed E, Pollak P, Laar TV, Zappia M. Consensus statement on the role of acute dopaminergicchallenge in Parkinson s disease. Mov Disord. 2001;16:197–201.View ArticlePubMedGoogle Scholar
- Merola A, Romagnolo A, Bernardini A, Rizzi L, Artusi CA, Lanotte M, Rizzone MG, Zibetti M, Lopiano L. Earlier versus later subthalamic deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord. 2015;21(8):972–5.View ArticlePubMedGoogle Scholar
- Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.View ArticlePubMedGoogle Scholar
- Jankovic J, McDermott M, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, et al. Variable expression of Parkinson s disease: a base-line analysis of the DATATOP cohort. Neurology. 1990;40(10):1529–34.View ArticlePubMedGoogle Scholar
- Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase potential markers. Lancet Neurol. 2009;8:1158–71.View ArticlePubMedGoogle Scholar
- Mestre TA, Espay AJ, Marras C, Eckman MH, Pollak P, Lang AE. Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. Mov Disord. 2014;29(14):1751–6.View ArticlePubMedGoogle Scholar
- Deuschl G, Schupbach M, Knudsen K, Pinsker MO, Cornu P, Rau J, Agid Y, Schade-Brittinger C. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord. 2013;19(1):56–61.View ArticlePubMedGoogle Scholar
- Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290–304.View ArticlePubMedGoogle Scholar
- Leranth CRR, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci. 2000;20:8604–9.PubMedGoogle Scholar
- Henderson VW. The neurology of menopause. Neurologist. 2006;12(3):149–59.View ArticlePubMedGoogle Scholar
- Gillies GE, Murray HE, Dexter D, McArthur S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav. 2004;78(3):513–22.View ArticlePubMedGoogle Scholar
- Yadav R, Shukla G, Goyal V, Singh S, Behari M. A case control study of women with Parkinson's disease and their fertility characteristics. J Neurol Sci. 2012;319(1–2):135–8.View ArticlePubMedGoogle Scholar
- Gerlach M, Riederer P. Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm. 2006;103:987–1041.View ArticleGoogle Scholar
- Dluzen DE, McDermott JL, Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J Neurochem. 1996;66:658–66.View ArticlePubMedGoogle Scholar
- Bejjani BP, Gervais D, Arnulf I, Papadopoulos S, Demeret S, Bonnet AM, Cornu P, Damier P, Agid Y. Axial parkinsonian symptoms can be improved:the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2000;68:595–600.View ArticlePubMedPubMed CentralGoogle Scholar
- Devos D, Defebvre L, Bordet R. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease. Fundam Clin Pharmacol. 2010;24(4):407–21.View ArticlePubMedGoogle Scholar
- Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson disease. Nat Rev Neurol. 2015;11(2):98–110.View ArticlePubMedGoogle Scholar
- Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol. 2012;8(8):435–42.PubMedGoogle Scholar